Lipocine Announces Tentative Approval of TLANDO

SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/— Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news